Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use ...

Recent label updates for Bristol Myers’ Camzyos should read positively for obstructive hypertrophic cardiomyopathy patients and physicians, as they could lead to greater categor ...

U.K. regulators cleared a multiple myeloma drug GSK withdrew from market three years ago. Elsewhere, an investment firm pressed Elevation Oncology to liquidate and the FDA relaxed risk monitoring ...

Merida Biosciences has emerged from Third Rock Ventures with $121 million in first-round financing for a pipeline of drugs ...

We recently published a list of the 10 Best High Short Interest Stocks to Buy Now. In this article, we are going to take a ...

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635 (c) ...

The lack of effect on QoL and oxygen consumption help cement the idea that the disease isn’t the same as obstructive HCM.

Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns.

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...